AUTHORS
Maria Rosario Capeding, Edison Alberto, Arijit Sil, Tarun Saluja, Samuel Teshome, Deok Ryun Kim, Ju Yeon Park, Jae Seung Yang, Suchada Chinaworapong, Jiwook Park, Sue-Kyoung Jo, Yun Chon, Seon-Young Yang, Dong Soo Ham, Ji Hwa Ryu, Julia Lynch, Jerome H. Kim, Hun Kim, Jean-Louis Excler, T. Anh Wartel, Sushant Sahastrabuddhe
ABSTRACT
Typhoid fever remains an important public health problem in developing countries and is endemic in many parts of Asia and Africa where the incidence of disease typically peaks in school-aged children. Age restrictions and other limitations of existing oral live-attenuated typhoid and parenteral Vi polysaccharide vaccines have triggered the development of Vi conjugate vaccines with improved immunological properties, use in younger age range, and longer durability of protection. We present the safety, reactogenicity, and immunogenicity data from a Phase II study after a single dose of Vi polysaccharide conjugated to diphtheria toxoid (Vi-DT) conducted in 6–23-month old Filipino children.
Click here to read the article, published in ScienceDirect.
